ONTOLOGY REPORT - ANNOTATIONS
|
|||||||||||||||||||||||||||||||
actinomycin D
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Symbol | Object Name | GBrowse | Qualifiers | Evidence | Chr | Start | Stop | Reference | Source | ||
| G | ABCB1 | ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
|
decreases response to substance | ISO | 7 | 87,133,179 | 87,342,639 | RGD:6480464 | CTD | |
| G | ABCB1 | ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
|
decreases response to substance | EXP | 7 | 87,133,179 | 87,342,639 | RGD:6480464 | CTD | |
| G | ABCB1 | ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
|
multiple interactions | EXP | 7 | 87,133,179 | 87,342,639 | RGD:6480464 | CTD | |
| G | ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 |
|
decreases response to substance | EXP | 16 | 16,043,434 | 16,236,931 | RGD:6480464 | CTD | |
| G | ABCC1 | ATP-binding cassette, sub-family C (CFTR/MRP), member 1 |
|
decreases response to substance | ISO | 16 | 16,043,434 | 16,236,931 | RGD:6480464 | CTD | |
| G | ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
|
decreases response to substance | ISO | 10 | 101,542,463 | 101,611,662 | RGD:6480464 | CTD | |
| G | ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
|
multiple interactions | ISO | 10 | 101,542,463 | 101,611,662 | RGD:6480464 | CTD | |
| G | ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 |
|
multiple interactions | EXP | 4 | 89,011,416 | 89,152,474 | RGD:6480464 | CTD | |
| G | ABHD3 | abhydrolase domain containing 3 |
|
increases expression | EXP | 18 | 19,230,858 | 19,284,766 | RGD:6480464 | CTD | |
| G | ABP1 | amiloride binding protein 1 (amine oxidase (copper-containing)) |
|
multiple interactions | ISO | 7 | 150,549,573 | 150,558,379 | RGD:6480464 | CTD | |
| G | ABP1 | amiloride binding protein 1 (amine oxidase (copper-containing)) |
|
multiple interactions | ISO | 7 | 150,549,573 | 150,558,379 | RGD:6480464 | CTD | |
| G | ACE | angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
multiple interactions | ISO | 17 | 61,554,422 | 61,575,741 | RGD:6480464 | CTD | |
| G | ACSL6 | acyl-CoA synthetase long-chain family member 6 |
|
multiple interactions | ISO | 5 | 131,285,666 | 131,347,761 | RGD:6480464 | CTD | |
| G | ADAM9 | ADAM metallopeptidase domain 9 |
|
multiple interactions | EXP | 8 | 38,854,505 | 38,962,780 | RGD:6480464 | CTD | |
| G | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions | EXP | 1 | 230,838,269 | 230,850,336 | RGD:6480464 | CTD | |
| G | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions | EXP | 1 | 230,838,269 | 230,850,336 | RGD:6480464 | CTD | |
| G | AGT | angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions | ISO | 1 | 230,838,269 | 230,850,336 | RGD:6480464 | CTD | |
| G | AHR | aryl hydrocarbon receptor |
|
multiple interactions | EXP | 7 | 17,338,276 | 17,385,775 | RGD:6480464 | CTD | |
| G | AHR | aryl hydrocarbon receptor |
|
multiple interactions | ISO | 7 | 17,338,276 | 17,385,775 | RGD:6480464 | CTD | |
| G | AICDA | activation-induced cytidine deaminase |
|
multiple interactions | ISO | 12 | 8,754,762 | 8,765,442 | RGD:6480464 | CTD | |
| G | AIFM1 | apoptosis-inducing factor, mitochondrion-associated, 1 |
|
multiple interactions | EXP | X | 129,263,337 | 129,299,861 | RGD:6480464 | CTD | |
| G | AKT1 | v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions | ISO | 14 | 105,235,686 | 105,262,080 | RGD:6480464 | CTD | |
| G | AKT1 | v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions | EXP | 14 | 105,235,686 | 105,262,080 | RGD:6480464 | CTD | |
| G | ALPI | alkaline phosphatase, intestinal |
|
multiple interactions | ISO | 2 | 233,320,833 | 233,324,742 | RGD:6480464 | CTD | |
| G | ARHGDIB | Rho GDP dissociation inhibitor (GDI) beta |
|
increases expression | EXP | 12 | 15,094,950 | 15,114,562 | RGD:6480464 | CTD | |
| G | ARNT | aryl hydrocarbon receptor nuclear translocator |
|
multiple interactions | ISO | 1 | 150,782,181 | 150,849,244 | RGD:6480464 | CTD | |
| G | ATF4 | activating transcription factor 4 (tax-responsive enhancer element B67) |
|
multiple interactions | EXP | 22 | 39,916,569 | 39,918,691 | RGD:6480464 | CTD | |
| G | AVP | arginine vasopressin |
|
multiple interactions | ISO | 20 | 3,063,202 | 3,065,370 | RGD:6480464 | CTD | |
| G | AXL | AXL receptor tyrosine kinase |
|
increases expression | EXP | 19 | 41,725,108 | 41,767,671 | RGD:6480464 | CTD | |
| G | BAG3 | BCL2-associated athanogene 3 |
|
multiple interactions | EXP | 10 | 121,410,882 | 121,437,331 | RGD:6480464 | CTD | |
| G | BAK1 | BCL2-antagonist/killer 1 |
|
multiple interactions | ISO | 6 | 33,540,323 | 33,548,070 | RGD:6480464 | CTD | |
| G | BAX | BCL2-associated X protein |
|
increases expression | EXP | 19 | 49,458,117 | 49,465,055 | RGD:6480464 | CTD | |
| G | BAX | BCL2-associated X protein |
|
increases expression | EXP | 19 | 49,458,117 | 49,465,055 | RGD:6480464 | CTD | |
| G | BAX | BCL2-associated X protein |
|
multiple interactions | EXP | 19 | 49,458,117 | 49,465,055 | RGD:6480464 | CTD | |
| G | BAX | BCL2-associated X protein |
|
increases expression | EXP | 19 | 49,458,117 | 49,465,055 | RGD:6480464 | CTD | |
| G | BAX | BCL2-associated X protein |
|
multiple interactions | ISO | 19 | 49,458,117 | 49,465,055 | RGD:6480464 | CTD | |
| G | BBC3 | BCL2 binding component 3 |
|
increases expression | EXP | 19 | 47,724,079 | 47,736,023 | RGD:6480464 | CTD | |
| G | BCL2 | B-cell CLL/lymphoma 2 |
|
multiple interactions | EXP | 18 | 60,790,579 | 60,986,613 | RGD:6480464 | CTD | |
| G | BCL2 | B-cell CLL/lymphoma 2 |
|
multiple interactions | EXP | 18 | 60,790,579 | 60,986,613 | RGD:6480464 | CTD | |
| G | BCL2 | B-cell CLL/lymphoma 2 |
|
decreases expression | EXP | 18 | 60,790,579 | 60,986,613 | RGD:6480464 | CTD | |
| G | BCL2 | B-cell CLL/lymphoma 2 |
|
decreases expression | EXP | 18 | 60,790,579 | 60,986,613 | RGD:6480464 | CTD | |
| G | BCL2 | B-cell CLL/lymphoma 2 |
|
multiple interactions | EXP | 18 | 60,790,579 | 60,986,613 | RGD:6480464 | CTD | |
| G | BCL2 | B-cell CLL/lymphoma 2 |
|
multiple interactions | EXP | 18 | 60,790,579 | 60,986,613 | RGD:6480464 | CTD | |
| G | BCL2A1 | BCL2-related protein A1 |
|
multiple interactions | EXP | 15 | 80,253,232 | 80,263,643 | RGD:6480464 | CTD | |
| G | BCL2L1 | BCL2-like 1 |
|
decreases expression | EXP | 20 | 30,252,261 | 30,310,656 | RGD:6480464 | CTD | |
| G | BCL2L1 | BCL2-like 1 |
|
increases expression | EXP | 20 | 30,252,261 | 30,310,656 | RGD:6480464 | CTD | |
| G | BCL2L1 | BCL2-like 1 |
|
increases expression | EXP | 20 | 30,252,261 | 30,310,656 | RGD:6480464 | CTD | |
| G | BCL2L1 | BCL2-like 1 |
|
multiple interactions | EXP | 20 | 30,252,261 | 30,310,656 | RGD:6480464 | CTD | |
| G | BCL2L11 | BCL2-like 11 (apoptosis facilitator) |
|
multiple interactions | ISO | 2 | 111,878,491 | 111,926,022 | RGD:6480464 | CTD | |
| G | BID | BH3 interacting domain death agonist |
|
multiple interactions | EXP | 22 | 18,216,906 | 18,257,431 | RGD:6480464 | CTD | |
| G | BID | BH3 interacting domain death agonist |
|
multiple interactions | ISO | 22 | 18,216,906 | 18,257,431 | RGD:6480464 | CTD | |
| G | BIRC3 | baculoviral IAP repeat containing 3 |
|
multiple interactions | EXP | 11 | 102,188,181 | 102,210,134 | RGD:6480464 | CTD | |
| G | BNIP3 | BCL2/adenovirus E1B 19kDa interacting protein 3 |
|
multiple interactions | ISO | 10 | 133,781,204 | 133,795,435 | RGD:6480464 | CTD | |
| G | BNIP3 | BCL2/adenovirus E1B 19kDa interacting protein 3 |
|
multiple interactions | ISO | 10 | 133,781,204 | 133,795,435 | RGD:6480464 | CTD | |
| G | BSDC1 | BSD domain containing 1 |
|
increases expression | EXP | 1 | 32,830,704 | 32,860,062 | RGD:6480464 | CTD | |
| G | CACNA1G | calcium channel, voltage-dependent, T type, alpha 1G subunit |
|
multiple interactions | ISO | 17 | 48,638,429 | 48,704,835 | RGD:6480464 | CTD | |
| G | CACNA1H | calcium channel, voltage-dependent, T type, alpha 1H subunit |
|
multiple interactions | ISO | 16 | 1,203,241 | 1,271,772 | RGD:6480464 | CTD | |
| G | CASP2 | caspase 2, apoptosis-related cysteine peptidase |
|
increases cleavage | EXP | 7 | 142,985,308 | 143,004,789 | RGD:6480464 | CTD | |
| G | CASP3 | caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions | EXP | 4 | 185,548,850 | 185,570,629 | RGD:6480464 | CTD | |
| G | CASP3 | caspase 3, apoptosis-related cysteine peptidase |
|
decreases expression | EXP | 4 | 185,548,850 | 185,570,629 | RGD:6480464 | CTD | |
| G | CASP3 | caspase 3, apoptosis-related cysteine peptidase |
|
increases activity | EXP | 4 | 185,548,850 | 185,570,629 | RGD:6480464 | CTD | |
| G | CASP3 | caspase 3, apoptosis-related cysteine peptidase |
|
multiple interactions | EXP | 4 | 185,548,850 | 185,570,629 | RGD:6480464 | CTD | |
| G | CASP7 | caspase 7, apoptosis-related cysteine peptidase |
|
multiple interactions | EXP | 10 | 115,438,921 | 115,490,668 | RGD:6480464 | CTD | |
| G | CASP7 | caspase 7, apoptosis-related cysteine peptidase |
|
multiple interactions | EXP | 10 | 115,438,921 | 115,490,668 | RGD:6480464 | CTD | |
| G | CASP7 | caspase 7, apoptosis-related cysteine peptidase |
|
decreases expression | EXP | 10 | 115,438,921 | 115,490,668 | RGD:6480464 | CTD | |
| G | CASP7 | caspase 7, apoptosis-related cysteine peptidase |
|
multiple interactions | EXP | 10 | 115,438,921 | 115,490,668 | RGD:6480464 | CTD | |
| G | CASP8 | caspase 8, apoptosis-related cysteine peptidase |
|
decreases expression | EXP | 2 | 202,098,166 | 202,152,434 | RGD:6480464 | CTD | |
| G | CASP9 | caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions | EXP | 1 | 15,818,769 | 15,851,285 | RGD:6480464 | CTD | |
| G | CAV1 | caveolin 1, caveolae protein, 22kDa |
|
multiple interactions | EXP | 7 | 116,164,839 | 116,201,239 | RGD:6480464 | CTD | |
| G | CCL11 | chemokine (C-C motif) ligand 11 |
|
multiple interactions | EXP | 17 | 32,612,687 | 32,615,199 | RGD:6480464 | CTD | |
| G | CCL2 | chemokine (C-C motif) ligand 2 |
|
multiple interactions | EXP | 17 | 32,582,296 | 32,584,222 | RGD:6480464 | CTD | |
| G | CCL2 | chemokine (C-C motif) ligand 2 |
|
multiple interactions | EXP | 17 | 32,582,296 | 32,584,222 | RGD:6480464 | CTD | |
| G | CCND1 | cyclin D1 |
|
decreases stability | ISO | 11 | 69,455,873 | 69,469,242 | RGD:6480464 | CTD | |
| G | CD1D | CD1d molecule |
|
multiple interactions | EXP | 1 | 158,149,737 | 158,156,217 | RGD:6480464 | CTD | |
| G | CD28 | CD28 molecule |
|
multiple interactions | EXP | 2 | 204,571,198 | 204,603,635 | RGD:6480464 | CTD | |
| G | CDKN1A | cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
multiple interactions | EXP | 6 | 36,644,237 | 36,655,116 | RGD:6480464 | CTD | |
| G | CDKN1A | cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
|
decreases expression | EXP | 6 | 36,644,237 | 36,655,116 | RGD:6480464 | CTD | |
| G | CEBPB | CCAAT/enhancer binding protein (C/EBP), beta |
|
decreases expression | EXP | 20 | 48,807,120 | 48,809,227 | RGD:6480464 | CTD | |
| G | CEL | carboxyl ester lipase |
|
increases expression | EXP | 9 | 135,937,365 | 135,947,248 | RGD:6480464 | CTD | |
| G | CFLAR | CASP8 and FADD-like apoptosis regulator |
|
decreases expression | EXP | 2 | 201,980,877 | 202,037,411 | RGD:6480464 | CTD | |
| G | CFLAR | CASP8 and FADD-like apoptosis regulator |
|
decreases expression | EXP | 2 | 201,980,877 | 202,037,411 | RGD:6480464 | CTD | |
| G | CKB | creatine kinase, brain |
|
multiple interactions | ISO | 14 | 103,985,995 | 103,989,196 | RGD:6480464 | CTD | |
| G | CLMN | calmin (calponin-like, transmembrane) |
|
multiple interactions | EXP | 14 | 95,648,276 | 95,786,245 | RGD:6480464 | CTD | |
| G | CNR1 | cannabinoid receptor 1 (brain) |
|
multiple interactions | EXP | 6 | 88,849,583 | 88,875,767 | RGD:6480464 | CTD | |
| G | CNR2 | cannabinoid receptor 2 (macrophage) |
|
multiple interactions | EXP | 1 | 24,200,460 | 24,239,817 | RGD:6480464 | CTD | |
| G | COL1A1 | collagen, type I, alpha 1 |
|
multiple interactions | EXP | 17 | 48,261,457 | 48,279,000 | RGD:6480464 | CTD | |
| G | COL1A2 | collagen, type I, alpha 2 |
|
multiple interactions | ISO | 7 | 94,023,873 | 94,060,544 | RGD:6480464 | CTD | |
| G | CRABP2 | cellular retinoic acid binding protein 2 |
|
increases expression | EXP | 1 | 156,669,398 | 156,675,608 | RGD:6480464 | CTD | |
| G | CSF2 | colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions | ISO | 5 | 131,409,485 | 131,411,863 | RGD:6480464 | CTD | |
| G | CSF2 | colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions | EXP | 5 | 131,409,485 | 131,411,863 | RGD:6480464 | CTD | |
| G | CYCS | cytochrome c, somatic |
|
multiple interactions | ISO | 7 | 25,158,270 | 25,164,980 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | EXP | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | EXP | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | EXP | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | ISO | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | ISO | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | ISO | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | ISO | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | ISO | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | ISO | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | EXP | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | EXP | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | EXP | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | ISO | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 1 |
|
multiple interactions | EXP | 15 | 75,011,883 | 75,017,877 | RGD:6480464 | CTD | |
| G | CYP1A2 | cytochrome P450, family 1, subfamily A, polypeptide 2 |
|
multiple interactions | EXP | 15 | 75,041,184 | 75,048,941 | RGD:6480464 | CTD | |
| G | CYP1B1 | cytochrome P450, family 1, subfamily B, polypeptide 1 |
|
multiple interactions | EXP | 2 | 38,294,746 | 38,303,323 | RGD:6480464 | CTD | |
| G | CYP1B1 | cytochrome P450, family 1, subfamily B, polypeptide 1 |
|
multiple interactions | ISO | 2 | 38,294,746 | 38,303,323 | RGD:6480464 | CTD | |
| G | CYP1B1 | cytochrome P450, family 1, subfamily B, polypeptide 1 |
|
decreases expression | ISO | 2 | 38,294,746 | 38,303,323 | RGD:6480464 | CTD | |
| G | CYP1B1 | cytochrome P450, family 1, subfamily B, polypeptide 1 |
|
multiple interactions | ISO | 2 | 38,294,746 | 38,303,323 | RGD:6480464 | CTD | |
| G | CYP2F1 | cytochrome P450, family 2, subfamily F, polypeptide 1 |
|
multiple interactions | EXP | 19 | 41,620,353 | 41,634,281 | RGD:6480464 | CTD | |
| G | CYP2S1 | cytochrome P450, family 2, subfamily S, polypeptide 1 |
|
multiple interactions | ISO | 19 | 41,699,115 | 41,713,444 | RGD:6480464 | CTD | |
| G | CYP3A4 | cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
multiple interactions | ISO | 7 | 99,354,583 | 99,381,811 | RGD:6480464 | CTD | |
| G | CYP3A4 | cytochrome P450, family 3, subfamily A, polypeptide 4 |
|
multiple interactions | EXP | 7 | 99,354,583 | 99,381,811 | RGD:6480464 | CTD | |
| G | DDAH2 | dimethylarginine dimethylaminohydrolase 2 |
|
multiple interactions | EXP | 6 | 31,694,817 | 31,698,039 | RGD:6480464 | CTD | |
| G | DIO3 | deiodinase, iodothyronine, type III |
|
multiple interactions | ISO | 14 | 102,027,688 | 102,029,789 | RGD:6480464 | CTD | |
| G | DPYSL4 | dihydropyrimidinase-like 4 |
|
increases expression | EXP | 10 | 134,000,414 | 134,019,280 | RGD:6480464 | CTD | |
| G | DSCR6 | Down syndrome critical region gene 6 |
|
increases expression | EXP | 21 | 38,378,863 | 38,391,959 | RGD:6480464 | CTD | |
| G | EDNRA | endothelin receptor type A |
|
multiple interactions | ISO | 4 | 148,402,069 | 148,466,106 | RGD:6480464 | CTD | |
| G | EDNRB | endothelin receptor type B |
|
multiple interactions | ISO | 13 13 |
78,469,616 78,513,393 |
78,549,664 78,549,674 |
RGD:6480464 | CTD | |
| G | EDNRB | endothelin receptor type B |
|
multiple interactions | ISO | 13 13 |
78,469,616 78,513,393 |
78,549,664 78,549,674 |
RGD:6480464 | CTD | |
| G | EDNRB | endothelin receptor type B |
|
multiple interactions | ISO | 13 13 |
78,469,616 78,513,393 |
78,549,664 78,549,674 |
RGD:6480464 | CTD | |
| G | EFNB2 | ephrin-B2 |
|
multiple interactions | EXP | 13 | 107,142,079 | 107,187,388 | RGD:6480464 | CTD | |
| G | EGF | epidermal growth factor |
|
multiple interactions | ISO | 4 | 110,834,040 | 110,934,118 | RGD:6480464 | CTD | |
| G | EGFR | epidermal growth factor receptor |
|
multiple interactions | ISO | 7 | 55,086,725 | 55,275,031 | RGD:6480464 | CTD | |
| G | EGR1 | early growth response 1 |
|
multiple interactions | ISO | 5 | 137,801,181 | 137,805,004 | RGD:6480464 | CTD | |
| G | ELOVL3 | ELOVL fatty acid elongase 3 |
|
multiple interactions | ISO | 10 | 103,986,143 | 103,989,346 | RGD:6480464 | CTD | |
| G | EMP1 | epithelial membrane protein 1 |
|
increases expression | EXP | 12 | 13,349,602 | 13,369,708 | RGD:6480464 | CTD | |
| G | EMP3 | epithelial membrane protein 3 |
|
increases expression | EXP | 19 | 48,828,629 | 48,833,810 | RGD:6480464 | CTD | |
| G | FADD | Fas (TNFRSF6)-associated via death domain |
|
decreases expression | EXP | 11 | 70,049,269 | 70,053,508 | RGD:6480464 | CTD | |
| G | FADS3 | fatty acid desaturase 3 |
|
increases expression | EXP | 11 | 61,640,998 | 61,659,006 | RGD:6480464 | CTD | |
| G | FBL | fibrillarin |
|
affects localization | EXP | 19 | 40,325,093 | 40,337,054 | RGD:6480464 | CTD | |
| G | FCAR | Fc fragment of IgA, receptor for |
|
multiple interactions | EXP | 19 | 55,385,549 | 55,401,839 | RGD:6480464 | CTD | |
| G | FGFR1 | fibroblast growth factor receptor 1 |
|
multiple interactions | ISO | 8 | 38,268,656 | 38,326,352 | RGD:6480464 | CTD | |
| G | FHL1 | four and a half LIM domains 1 |
|
multiple interactions | ISO | X | 135,228,861 | 135,293,518 | RGD:6480464 | CTD | |
| G | FLNC | filamin C, gamma |
|
increases expression | EXP | 7 | 128,470,483 | 128,499,328 | RGD:6480464 | CTD | |
| G | FN1 | fibronectin 1 |
|
multiple interactions | EXP | 2 | 216,225,177 | 216,300,791 | RGD:6480464 | CTD | |
| G | FOS | FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions | ISO | 14 | 75,745,481 | 75,748,937 | RGD:6480464 | CTD | |
| G | FOS | FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions | ISO | 14 | 75,745,481 | 75,748,937 | RGD:6480464 | CTD | |
| G | FOS | FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions | ISO | 14 | 75,745,481 | 75,748,937 | RGD:6480464 | CTD | |
| G | FOS | FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions | ISO | 14 | 75,745,481 | 75,748,937 | RGD:6480464 | CTD | |
| G | FOS | FBJ murine osteosarcoma viral oncogene homolog |
|
decreases expression | ISO | 14 | 75,745,481 | 75,748,937 | RGD:6480464 | CTD | |
| G | FOS | FBJ murine osteosarcoma viral oncogene homolog |
|
multiple interactions | EXP | 14 | 75,745,481 | 75,748,937 | RGD:6480464 | CTD | |
| G | G6PD | glucose-6-phosphate dehydrogenase |
|
multiple interactions | ISO | X | 153,759,606 | 153,775,787 | RGD:6480464 | CTD | |
| G | GADD45A | growth arrest and DNA-damage-inducible, alpha |
|
multiple interactions | EXP | 1 | 68,150,860 | 68,154,021 | RGD:6480464 | CTD | |
| G | GADD45A | growth arrest and DNA-damage-inducible, alpha |
|
increases expression | EXP | 1 | 68,150,860 | 68,154,021 | RGD:6480464 | CTD | |
| G | GALM | galactose mutarotase (aldose 1-epimerase) |
|
multiple interactions | EXP | 2 | 38,893,052 | 38,961,909 | RGD:6480464 | CTD | |
| G | GAPDH | glyceraldehyde-3-phosphate dehydrogenase |
|
increases expression | EXP | 12 | 6,643,585 | 6,647,537 | RGD:6480464 | CTD | |
| G | GAS6 | growth arrest-specific 6 |
|
multiple interactions | EXP | 13 | 114,523,522 | 114,567,046 | RGD:6480464 | CTD | |
| G | GAS6 | growth arrest-specific 6 |
|
increases degradation | EXP | 13 | 114,523,522 | 114,567,046 | RGD:6480464 | CTD | |
| G | GCLC | glutamate-cysteine ligase, catalytic subunit |
|
multiple interactions | EXP | 6 | 53,362,139 | 53,409,927 | RGD:6480464 | CTD | |
| G | GDF15 | growth differentiation factor 15 |
|
multiple interactions | EXP | 19 | 18,496,968 | 18,499,986 | RGD:6480464 | CTD | |
| G | GPR137B | G protein-coupled receptor 137B |
|
increases expression | EXP | 1 | 236,305,832 | 236,372,209 | RGD:6480464 | CTD | |
| G | GRM5 | glutamate receptor, metabotropic 5 |
|
multiple interactions | ISO | 11 | 88,237,744 | 88,796,816 | RGD:6480464 | CTD | |
| G | GSTA1 | glutathione S-transferase alpha 1 |
|
multiple interactions | ISO | 6 | 52,656,178 | 52,668,664 | RGD:6480464 | CTD | |
| G | GSTP1 | glutathione S-transferase pi 1 |
|
decreases response to substance | ISO | 11 | 67,351,066 | 67,354,124 | RGD:6480464 | CTD | |
| G | HIF1A | hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
multiple interactions | EXP | 14 | 62,162,119 | 62,214,977 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | EXP | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | EXP | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | EXP | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | EXP | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | ISO | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | ISO | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | ISO | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | ISO | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | EXP | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | EXP | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | ISO | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | EXP | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | ISO | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HMOX1 | heme oxygenase (decycling) 1 |
|
multiple interactions | EXP | 22 | 35,777,060 | 35,790,207 | RGD:6480464 | CTD | |
| G | HNRNPA1 | heterogeneous nuclear ribonucleoprotein A1 |
|
affects localization | ISO | 12 | 54,674,488 | 54,679,030 | RGD:6480464 | CTD | |
| G | HNRNPA1 | heterogeneous nuclear ribonucleoprotein A1 |
|
multiple interactions | ISO | 12 | 54,674,488 | 54,679,030 | RGD:6480464 | CTD | |
| G | HOMER3 | homer homolog 3 (Drosophila) |
|
increases expression | EXP | 19 | 19,040,010 | 19,052,041 | RGD:6480464 | CTD | |
| G | HRAS | v-Ha-ras Harvey rat sarcoma viral oncogene homolog |
|
multiple interactions | EXP | 11 | 532,242 | 535,550 | RGD:6480464 | CTD | |
| G | HSPA5 | heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) |
|
multiple interactions | ISO | 9 | 127,997,127 | 128,003,666 | RGD:6480464 | CTD | |
| G | HTR3A | 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic |
|
multiple interactions | ISO | 11 | 113,845,797 | 113,861,035 | RGD:6480464 | CTD | |
| G | ID1 | inhibitor of DNA binding 1, dominant negative helix-loop-helix protein |
|
multiple interactions | EXP | 20 | 30,193,086 | 30,194,318 | RGD:6480464 | CTD | |
| G | IER3 | immediate early response 3 |
|
multiple interactions | EXP | 6 | 30,710,976 | 30,712,327 | RGD:6480464 | CTD | |
| G | IER5 | immediate early response 5 |
|
increases expression | EXP | 1 | 181,057,638 | 181,059,979 | RGD:6480464 | CTD | |
| G | IFNA1 | interferon, alpha 1 |
|
multiple interactions | EXP | 9 | 21,440,453 | 21,441,315 | RGD:6480464 | CTD | |
| G | IFNB1 | interferon, beta 1, fibroblast |
|
multiple interactions | EXP | 9 | 21,077,104 | 21,077,943 | RGD:6480464 | CTD | |
| G | IFNG | interferon, gamma |
|
multiple interactions | EXP | 12 | 68,548,550 | 68,553,521 | RGD:6480464 | CTD | |
| G | IFNG | interferon, gamma |
|
multiple interactions | EXP | 12 | 68,548,550 | 68,553,521 | RGD:6480464 | CTD | |
| G | IL10 | interleukin 10 |
|
multiple interactions | ISO | 1 | 206,940,948 | 206,945,839 | RGD:6480464 | CTD | |
| G | IL11 | interleukin 11 |
|
multiple interactions | EXP | 19 | 55,875,750 | 55,881,831 | RGD:6480464 | CTD | |
| G | IL17A | interleukin 17A |
|
multiple interactions | ISO | 6 | 52,051,185 | 52,055,436 | RGD:6480464 | CTD | |
| G | IL17A | interleukin 17A |
|
multiple interactions | ISO | 6 | 52,051,185 | 52,055,436 | RGD:6480464 | CTD | |
| G | IL1B | interleukin 1, beta |
|
multiple interactions | EXP | 2 | 113,587,337 | 113,594,356 | RGD:6480464 | CTD | |
| G | IL1B | interleukin 1, beta |
|
multiple interactions | EXP | 2 | 113,587,337 | 113,594,356 | RGD:6480464 | CTD | |
| G | IL1B | interleukin 1, beta |
|
multiple interactions | EXP | 2 | 113,587,337 | 113,594,356 | RGD:6480464 | CTD | |
| G | IL1B | interleukin 1, beta |
|
multiple interactions | EXP | 2 | 113,587,337 | 113,594,356 | RGD:6480464 | CTD | |
| G | IL1B | interleukin 1, beta |
|
multiple interactions | ISO | 2 | 113,587,337 | 113,594,356 | RGD:6480464 | CTD | |
| G | IL1B | interleukin 1, beta |
|
multiple interactions | ISO | 2 | 113,587,337 | 113,594,356 | RGD:6480464 | CTD | |
| G | IL1B | interleukin 1, beta |
|
multiple interactions | EXP | 2 | 113,587,337 | 113,594,356 | RGD:6480464 | CTD | |
| G | IL27RA | interleukin 27 receptor, alpha |
|
increases expression | EXP | 19 | 14,142,552 | 14,163,731 | RGD:6480464 | CTD | |
| G | IL8 | interleukin 8 |
|
multiple interactions | EXP | 4 | 74,606,223 | 74,609,433 | RGD:6480464 | CTD | |
| G | IL8 | interleukin 8 |
|
multiple interactions | EXP | 4 | 74,606,223 | 74,609,433 | RGD:6480464 | CTD | |
| G | IL8 | interleukin 8 |
|
multiple interactions | EXP | 4 | 74,606,223 | 74,609,433 | RGD:6480464 | CTD | |
| G | IL8 | interleukin 8 |
|
multiple interactions | EXP | 4 | 74,606,223 | 74,609,433 | RGD:6480464 | CTD | |
| G | IL8 | interleukin 8 |
|
multiple interactions | EXP | 4 | 74,606,223 | 74,609,433 | RGD:6480464 | CTD | |
| G | IL8 | interleukin 8 |
|
multiple interactions | EXP | 4 | 74,606,223 | 74,609,433 | RGD:6480464 | CTD | |
| G | IL8 | interleukin 8 |
|
multiple interactions | EXP | 4 | 74,606,223 | 74,609,433 | RGD:6480464 | CTD | |
| G | IRF1 | interferon regulatory factor 1 |
|
multiple interactions | EXP | 5 | 131,817,301 | 131,826,465 | RGD:6480464 | CTD | |
| G | IRF1 | interferon regulatory factor 1 |
|
multiple interactions | EXP | 5 | 131,817,301 | 131,826,465 | RGD:6480464 | CTD | |
| G | ITGA2B | integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) |
|
increases expression | EXP | 17 | 42,449,550 | 42,466,873 | RGD:6480464 | CTD | |
| G | ITPR1 | inositol 1,4,5-trisphosphate receptor, type 1 |
|
multiple interactions | EXP | 3 | 4,535,032 | 4,889,524 | RGD:6480464 | CTD | |
| G | JAK2 | Janus kinase 2 |
|
multiple interactions | ISO | 9 | 4,985,245 | 5,128,183 | RGD:6480464 | CTD | |
| G | JUN | jun proto-oncogene |
|
multiple interactions | ISO | 1 | 59,246,463 | 59,249,785 | RGD:6480464 | CTD | |
| G | JUN | jun proto-oncogene |
|
multiple interactions | ISO | 1 | 59,246,463 | 59,249,785 | RGD:6480464 | CTD | |
| G | JUN | jun proto-oncogene |
|
decreases expression | ISO | 1 | 59,246,463 | 59,249,785 | RGD:6480464 | CTD | |
| G | JUN | jun proto-oncogene |
|
multiple interactions | ISO | 1 | 59,246,463 | 59,249,785 | RGD:6480464 | CTD | |
| G | KIF1A | kinesin family member 1A |
|
increases expression | EXP | 2 | 241,653,181 | 241,759,725 | RGD:6480464 | CTD | |
| G | KRT80 | keratin 80 |
|
increases expression | EXP | 12 | 52,562,780 | 52,585,784 | RGD:6480464 | CTD | |
| G | LAMC2 | laminin, gamma 2 |
|
increases expression | EXP | 1 | 183,155,174 | 183,214,262 | RGD:6480464 | CTD | |
| G | LEP | leptin |
|
multiple interactions | ISO | 7 | 127,881,331 | 127,897,682 | RGD:6480464 | CTD | |
| G | LGALS3 | lectin, galactoside-binding, soluble, 3 |
|
multiple interactions | EXP | 14 | 55,595,935 | 55,612,148 | RGD:6480464 | CTD | |
| G | LGALS7 | lectin, galactoside-binding, soluble, 7 |
|
increases expression | EXP | 19 | 39,261,608 | 39,264,157 | RGD:6480464 | CTD | |
| G | LMNB1 | lamin B1 |
|
decreases expression | EXP | 5 | 126,112,315 | 126,172,712 | RGD:6480464 | CTD | |
| G | MAP2K4 | mitogen-activated protein kinase kinase 4 |
|
decreases expression | EXP | 17 | 11,924,135 | 12,047,051 | RGD:6480464 | CTD | |
| G | MAP3K7 | mitogen-activated protein kinase kinase kinase 7 |
|
decreases expression | EXP | 6 | 91,223,292 | 91,297,020 | RGD:6480464 | CTD | |
| G | MAPK1 | mitogen-activated protein kinase 1 |
|
multiple interactions | EXP | 22 | 22,113,946 | 22,221,970 | RGD:6480464 | CTD | |
| G | MAPK1 | mitogen-activated protein kinase 1 |
|
increases expression | ISO | 22 | 22,113,946 | 22,221,970 | RGD:6480464 | CTD | |
| G | MAPK1 | mitogen-activated protein kinase 1 |
|
multiple interactions | ISO | 22 | 22,113,946 | 22,221,970 | RGD:6480464 | CTD | |
| G | MAPK3 | mitogen-activated protein kinase 3 |
|
multiple interactions | EXP | 16 | 30,125,426 | 30,134,630 | RGD:6480464 | CTD | |
| G | MAPK3 | mitogen-activated protein kinase 3 |
|
multiple interactions | ISO | 16 | 30,125,426 | 30,134,630 | RGD:6480464 | CTD | |
| G | MAPK3 | mitogen-activated protein kinase 3 |
|
increases expression | ISO | 16 | 30,125,426 | 30,134,630 | RGD:6480464 | CTD | |
| G | MCL1 | myeloid cell leukemia sequence 1 (BCL2-related) |
|
multiple interactions | EXP | 1 | 150,547,027 | 150,552,214 | RGD:6480464 | CTD | |
| G | MIR21 | microRNA 21 |
|
multiple interactions | EXP | 17 | 57,918,627 | 57,918,698 | RGD:6480464 | CTD | |
| G | MIR21 | microRNA 21 |
|
multiple interactions | EXP | 17 | 57,918,627 | 57,918,698 | RGD:6480464 | CTD | |
| G | MLLT11 | myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11 |
|
increases expression | EXP | 1 | 151,032,151 | 151,040,973 | RGD:6480464 | CTD | |
| G | MMP1 | matrix metallopeptidase 1 (interstitial collagenase) |
|
multiple interactions | EXP | 11 | 102,660,641 | 102,668,966 | RGD:6480464 | CTD | |
| G | MN1 | meningioma (disrupted in balanced translocation) 1 |
|
multiple interactions | EXP | 22 | 28,144,265 | 28,197,486 | RGD:6480464 | CTD | |
| G | MRPL41 | mitochondrial ribosomal protein L41 |
|
multiple interactions | EXP | 9 | 140,446,309 | 140,447,007 | RGD:6480464 | CTD | |
| G | MT2A | metallothionein 2A |
|
multiple interactions | EXP | 16 | 56,642,478 | 56,643,409 | RGD:6480464 | CTD | |
| G | MTTP | microsomal triglyceride transfer protein |
|
multiple interactions | ISO | 4 | 100,485,240 | 100,545,154 | RGD:6480464 | CTD | |
| G | MYC | v-myc myelocytomatosis viral oncogene homolog (avian) |
|
decreases expression | EXP | 8 | 128,748,315 | 128,753,680 | RGD:6480464 | CTD | |
| G | MYC | v-myc myelocytomatosis viral oncogene homolog (avian) |
|
decreases expression | EXP | 8 | 128,748,315 | 128,753,680 | RGD:6480464 | CTD | |
| G | MYC | v-myc myelocytomatosis viral oncogene homolog (avian) |
|
multiple interactions | ISO | 8 | 128,748,315 | 128,753,680 | RGD:6480464 | CTD | |
| G | MYC | v-myc myelocytomatosis viral oncogene homolog (avian) |
|
decreases expression | ISO | 8 | 128,748,315 | 128,753,680 | RGD:6480464 | CTD | |
| G | MYLK | myosin light chain kinase |
|
multiple interactions | EXP | 3 | 123,331,143 | 123,603,149 | RGD:6480464 | CTD | |
| G | NAV2 | neuron navigator 2 |
|
multiple interactions | EXP | 11 | 19,372,271 | 20,143,147 | RGD:6480464 | CTD | |
| G | NCF1 | neutrophil cytosolic factor 1 |
|
multiple interactions | EXP | 7 | 74,188,309 | 74,203,659 | RGD:6480464 | CTD | |
| G | NDRG1 | N-myc downstream regulated 1 |
|
multiple interactions | ISO | 8 | 134,249,414 | 134,309,547 | RGD:6480464 | CTD | |
| G | NEDD9 | neural precursor cell expressed, developmentally down-regulated 9 |
|
multiple interactions | EXP | 6 | 11,183,531 | 11,382,581 | RGD:6480464 | CTD | |
| G | NETO2 | neuropilin (NRP) and tolloid (TLL)-like 2 |
|
increases expression | EXP | 16 | 47,115,431 | 47,177,936 | RGD:6480464 | CTD | |
| G | NFE2L2 | nuclear factor (erythroid-derived 2)-like 2 |
|
multiple interactions | EXP | 2 | 178,095,031 | 178,129,859 | RGD:6480464 | CTD | |
| G | NFKB1 | nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
decreases expression | EXP | 4 | 103,422,486 | 103,538,459 | RGD:6480464 | CTD | |
| G | NFKB1 | nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions | EXP | 4 | 103,422,486 | 103,538,459 | RGD:6480464 | CTD | |
| G | NFKBIA | nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions | EXP | 14 | 35,870,716 | 35,873,960 | RGD:6480464 | CTD | |
| G | NOS2 | nitric oxide synthase 2, inducible |
|
multiple interactions | ISO | 17 | 26,083,792 | 26,127,555 | RGD:6480464 | CTD | |
| G | NPPC | natriuretic peptide C |
|
multiple interactions | ISO | 2 | 232,786,805 | 232,791,038 | RGD:6480464 | CTD | |
| G | NQO1 | NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions | ISO | 16 | 69,743,304 | 69,760,533 | RGD:6480464 | CTD | |
| G | NQO1 | NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions | ISO | 16 | 69,743,304 | 69,760,533 | RGD:6480464 | CTD | |
| G | NQO1 | NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions | ISO | 16 | 69,743,304 | 69,760,533 | RGD:6480464 | CTD | |
| G | NQO1 | NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions | ISO | 16 | 69,743,304 | 69,760,533 | RGD:6480464 | CTD | |
| G | NR0B2 | nuclear receptor subfamily 0, group B, member 2 |
|
multiple interactions | EXP | 1 | 27,237,975 | 27,240,567 | RGD:6480464 | CTD | |
| G | NR1I2 | nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions | ISO | 3 | 119,499,331 | 119,537,332 | RGD:6480464 | CTD | |
| G | NR1I2 | nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions | ISO | 3 | 119,499,331 | 119,537,332 | RGD:6480464 | CTD | |
| G | NR3C1 | nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
|
multiple interactions | ISO | 5 | 142,657,496 | 142,815,077 | RGD:6480464 | CTD | |
| G | NTHL1 | nth endonuclease III-like 1 (E. coli) |
|
decreases expression | EXP | 16 | 2,089,816 | 2,097,867 | RGD:6480464 | CTD | |
| G | PAPPA | pregnancy-associated plasma protein A, pappalysin 1 |
|
multiple interactions | EXP | 9 | 118,916,071 | 119,164,600 | RGD:6480464 | CTD | |
| G | PARP1 | poly (ADP-ribose) polymerase 1 |
|
multiple interactions | EXP | 1 | 226,548,392 | 226,595,801 | RGD:6480464 | CTD | |
| G | PARP1 | poly (ADP-ribose) polymerase 1 |
|
multiple interactions | EXP | 1 | 226,548,392 | 226,595,801 | RGD:6480464 | CTD | |
| G | PARP1 | poly (ADP-ribose) polymerase 1 |
|
multiple interactions | ISO | 1 | 226,548,392 | 226,595,801 | RGD:6480464 | CTD | |
| G | PCNA | proliferating cell nuclear antigen |
|
decreases expression | ISO | 20 | 5,095,599 | 5,107,268 | RGD:6480464 | CTD | |
| G | PCNA | proliferating cell nuclear antigen |
|
multiple interactions | EXP | 20 | 5,095,599 | 5,107,268 | RGD:6480464 | CTD | |
| G | PLAT | plasminogen activator, tissue |
|
multiple interactions | EXP | 8 | 42,032,236 | 42,065,194 | RGD:6480464 | CTD | |
| G | PLAU | plasminogen activator, urokinase |
|
multiple interactions | EXP | 10 | 75,670,862 | 75,677,259 | RGD:6480464 | CTD | |
| G | PLAU | plasminogen activator, urokinase |
|
increases expression | EXP | 10 | 75,670,862 | 75,677,259 | RGD:6480464 | CTD | |
| G | PLD1 | phospholipase D1, phosphatidylcholine-specific |
|
multiple interactions | EXP | 3 | 171,318,195 | 171,528,284 | RGD:6480464 | CTD | |
| G | PLD2 | phospholipase D2 |
|
multiple interactions | ISO | 17 | 4,710,396 | 4,726,727 | RGD:6480464 | CTD | |
| G | POMT1 | protein-O-mannosyltransferase 1 |
|
increases expression | EXP | 9 | 134,378,289 | 134,399,193 | RGD:6480464 | CTD | |
| G | PRDX1 | peroxiredoxin 1 |
|
multiple interactions | ISO | 1 | 45,976,707 | 45,988,562 | RGD:6480464 | CTD | |
| G | PRDX6 | peroxiredoxin 6 |
|
multiple interactions | ISO | 1 | 173,446,486 | 173,457,946 | RGD:6480464 | CTD | |
| G | PRKCD | protein kinase C, delta |
|
multiple interactions | EXP | 3 | 53,195,223 | 53,226,733 | RGD:6480464 | CTD | |
| G | PRKCD | protein kinase C, delta |
|
multiple interactions | ISO | 3 | 53,195,223 | 53,226,733 | RGD:6480464 | CTD | |
| G | PRL | prolactin |
|
multiple interactions | ISO | 6 | 22,287,473 | 22,303,082 | RGD:6480464 | CTD | |
| G | PROCR | protein C receptor, endothelial |
|
increases expression | EXP | 20 | 33,759,774 | 33,765,165 | RGD:6480464 | CTD | |
| G | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions | EXP | 1 | 186,640,944 | 186,649,559 | RGD:6480464 | CTD | |
| G | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions | ISO | 1 | 186,640,944 | 186,649,559 | RGD:6480464 | CTD | |
| G | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
decreases expression | ISO | 1 | 186,640,944 | 186,649,559 | RGD:6480464 | CTD | |
| G | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions | ISO | 1 | 186,640,944 | 186,649,559 | RGD:6480464 | CTD | |
| G | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions | EXP | 1 | 186,640,944 | 186,649,559 | RGD:6480464 | CTD | |
| G | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions | ISO | 1 | 186,640,944 | 186,649,559 | RGD:6480464 | CTD | |
| G | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions | EXP | 1 | 186,640,944 | 186,649,559 | RGD:6480464 | CTD | |
| G | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
|
multiple interactions | EXP | 1 | 186,640,944 | 186,649,559 | RGD:6480464 | CTD | |
| G | PTK2 | protein tyrosine kinase 2 |
|
decreases expression | ISO | 8 | 141,668,481 | 142,011,412 | RGD:6480464 | CTD | |
| G | REL | v-rel reticuloendotheliosis viral oncogene homolog (avian) |
|
multiple interactions | EXP | 2 | 61,108,752 | 61,150,178 | RGD:6480464 | CTD | |
| G | RELA | v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions | EXP | 11 | 65,421,067 | 65,430,443 | RGD:6480464 | CTD | |
| G | REN | renin |
|
multiple interactions | EXP | 1 | 204,123,944 | 204,135,465 | RGD:6480464 | CTD | |
| G | RETSAT | retinol saturase (all-trans-retinol 13,14-reductase) |
|
increases expression | EXP | 2 | 85,569,078 | 85,581,821 | RGD:6480464 | CTD | |
| G | RNY1 | RNA, Ro-associated Y1 |
|
increases degradation | EXP | 7 | 148,684,228 | 148,684,340 | RGD:6480464 | CTD | |
| G | RNY3 | RNA, Ro-associated Y3 |
|
increases degradation | EXP | 7 | 148,680,847 | 148,680,948 | RGD:6480464 | CTD | |
| G | RNY4 | RNA, Ro-associated Y4 |
|
increases degradation | EXP | 7 | 148,660,407 | 148,660,502 | RGD:6480464 | CTD | |
| G | RNY5 | RNA, Ro-associated Y5 |
|
increases degradation | EXP | 7 | 148,638,580 | 148,638,663 | RGD:6480464 | CTD | |
| G | ROS1 | c-ros oncogene 1 , receptor tyrosine kinase |
|
increases expression | EXP | 6 | 117,609,530 | 117,747,018 | RGD:6480464 | CTD | |
| G | RPL34 | ribosomal protein L34 |
|
increases expression | EXP | 4 | 109,541,722 | 109,551,640 | RGD:6480464 | CTD | |
| G | RPS6KB1 | ribosomal protein S6 kinase, 70kDa, polypeptide 1 |
|
multiple interactions | EXP | 17 | 57,970,443 | 58,027,787 | RGD:6480464 | CTD | |
| G | RPS6KB1 | ribosomal protein S6 kinase, 70kDa, polypeptide 1 |
|
multiple interactions | ISO | 17 | 57,970,443 | 58,027,787 | RGD:6480464 | CTD | |
| G | RRAS | related RAS viral (r-ras) oncogene homolog |
|
increases expression | EXP | 19 | 50,138,552 | 50,143,400 | RGD:6480464 | CTD | |
| G | SAT1 | spermidine/spermine N1-acetyltransferase 1 |
|
multiple interactions | EXP | X | 23,801,275 | 23,804,327 | RGD:6480464 | CTD | |
| G | SCNN1B | sodium channel, non-voltage-gated 1, beta subunit |
|
multiple interactions | EXP | 16 | 23,313,591 | 23,392,620 | RGD:6480464 | CTD | |
| G | SCNN1G | sodium channel, non-voltage-gated 1, gamma subunit |
|
multiple interactions | EXP | 16 | 23,194,040 | 23,228,200 | RGD:6480464 | CTD | |
| G | SDC3 | syndecan 3 |
|
multiple interactions | ISO | 1 | 31,342,313 | 31,381,480 | RGD:6480464 | CTD | |
| G | SFN | stratifin |
|
increases expression | EXP | 1 | 27,189,633 | 27,190,947 | RGD:6480464 | CTD | |
| G | SLC25A14 | solute carrier family 25 (mitochondrial carrier, brain), member 14 |
|
multiple interactions | EXP | X | 129,474,047 | 129,507,335 | RGD:6480464 | CTD | |
| G | SLC2A2 | solute carrier family 2 (facilitated glucose transporter), member 2 |
|
multiple interactions | ISO | 3 | 170,714,137 | 170,744,768 | RGD:6480464 | CTD | |
| G | SLC2A5 | solute carrier family 2 (facilitated glucose/fructose transporter), member 5 |
|
multiple interactions | ISO | 1 | 9,097,005 | 9,129,887 | RGD:6480464 | CTD | |
| G | SLC30A2 | solute carrier family 30 (zinc transporter), member 2 |
|
multiple interactions | ISO | 1 | 26,364,514 | 26,372,604 | RGD:6480464 | CTD | |
| G | SLC30A5 | solute carrier family 30 (zinc transporter), member 5 |
|
multiple interactions | EXP | 5 | 68,389,776 | 68,426,899 | RGD:6480464 | CTD | |
| G | SLC39A10 | solute carrier family 39 (zinc transporter), member 10 |
|
multiple interactions | ISO | 2 | 196,521,532 | 196,602,426 | RGD:6480464 | CTD | |
| G | SLC39A4 | solute carrier family 39 (zinc transporter), member 4 |
|
multiple interactions | ISO | 8 | 145,637,798 | 145,642,273 | RGD:6480464 | CTD | |
| G | SOD2 | superoxide dismutase 2, mitochondrial |
|
multiple interactions | EXP | 6 | 160,100,148 | 160,114,353 | RGD:6480464 | CTD | |
| G | SOD2 | superoxide dismutase 2, mitochondrial |
|
multiple interactions | EXP | 6 | 160,100,148 | 160,114,353 | RGD:6480464 | CTD | |
| G | SOD2 | superoxide dismutase 2, mitochondrial |
|
multiple interactions | EXP | 6 | 160,100,148 | 160,114,353 | RGD:6480464 | CTD | |
| G | SOD2 | superoxide dismutase 2, mitochondrial |
|
multiple interactions | ISO | 6 | 160,100,148 | 160,114,353 | RGD:6480464 | CTD | |
| G | SOD2 | superoxide dismutase 2, mitochondrial |
|
multiple interactions | ISO | 6 | 160,100,148 | 160,114,353 | RGD:6480464 | CTD | |
| G | SOS1 | son of sevenless homolog 1 (Drosophila) |
|
decreases expression | EXP | 2 | 39,208,690 | 39,347,604 | RGD:6480464 | CTD | |
| G | SPATA18 | spermatogenesis associated 18 |
|
increases expression | EXP | 4 | 52,917,593 | 52,963,458 | RGD:6480464 | CTD | |
| G | STAT1 | signal transducer and activator of transcription 1, 91kDa |
|
increases expression | EXP | 2 | 191,833,762 | 191,878,976 | RGD:6480464 | CTD | |
| G | STMN3 | stathmin-like 3 |
|
increases expression | EXP | 20 | 62,271,061 | 62,284,780 | RGD:6480464 | CTD | |
| G | STOM | stomatin |
|
increases expression | EXP | 9 | 124,101,266 | 124,132,582 | RGD:6480464 | CTD | |
| G | SULT1A1 | sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 |
|
multiple interactions | EXP | 16 | 28,616,908 | 28,634,907 | RGD:6480464 | CTD | |
| G | TAP1 | transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) |
|
increases expression | EXP | 6 | 32,812,986 | 32,821,748 | RGD:6480464 | CTD | |
| G | TAT | tyrosine aminotransferase |
|
multiple interactions | ISO | 16 | 71,600,754 | 71,610,998 | RGD:6480464 | CTD | |
| G | TAT | tyrosine aminotransferase |
|
multiple interactions | ISO | 16 | 71,600,754 | 71,610,998 | RGD:6480464 | CTD | |
| G | TCF4 | transcription factor 4 |
|
multiple interactions | ISO | 18 | 52,889,562 | 53,303,188 | RGD:6480464 | CTD | |
| G | TDO2 | tryptophan 2,3-dioxygenase |
|
affects activity | ISO | 4 | 156,824,845 | 156,841,558 | RGD:6480464 | CTD | |
| G | TGFB1 | transforming growth factor, beta 1 |
|
multiple interactions | EXP | 19 | 41,836,812 | 41,859,831 | RGD:6480464 | CTD | |
| G | TGFB1 | transforming growth factor, beta 1 |
|
multiple interactions | EXP | 19 | 41,836,812 | 41,859,831 | RGD:6480464 | CTD | |
| G | TGFB2 | transforming growth factor, beta 2 |
|
multiple interactions | EXP | 1 | 218,518,676 | 218,617,961 | RGD:6480464 | CTD | |
| G | THRA | thyroid hormone receptor, alpha |
|
multiple interactions | ISO | 17 | 38,218,446 | 38,250,120 | RGD:6480464 | CTD | |
| G | TIPARP | TCDD-inducible poly(ADP-ribose) polymerase |
|
multiple interactions | ISO | 3 | 156,392,205 | 156,424,559 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | EXP | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | EXP | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | EXP | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | EXP | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | EXP | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | EXP | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | ISO | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | EXP | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | EXP | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
increases response to substance | EXP | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | ISO | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | ISO | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNF | tumor necrosis factor |
|
multiple interactions | ISO | 6 | 31,543,344 | 31,546,113 | RGD:6480464 | CTD | |
| G | TNFAIP3 | tumor necrosis factor, alpha-induced protein 3 |
|
multiple interactions | EXP | 6 | 138,188,325 | 138,204,451 | RGD:6480464 | CTD | |
| G | TNFRSF10B | tumor necrosis factor receptor superfamily, member 10b |
|
decreases expression | EXP | 8 | 22,877,646 | 22,926,700 | RGD:6480464 | CTD | |
| G | TNFRSF10B | tumor necrosis factor receptor superfamily, member 10b |
|
multiple interactions | EXP | 8 | 22,877,646 | 22,926,700 | RGD:6480464 | CTD | |
| G | TNFSF10 | tumor necrosis factor (ligand) superfamily, member 10 |
|
multiple interactions | EXP | 3 | 172,223,298 | 172,241,297 | RGD:6480464 | CTD | |
| G | TNFSF9 | tumor necrosis factor (ligand) superfamily, member 9 |
|
increases expression | EXP | 19 | 6,531,010 | 6,535,939 | RGD:6480464 | CTD | |
| G | TOP1 | topoisomerase (DNA) I |
|
increases activity | ISO | 20 | 39,657,462 | 39,753,127 | RGD:6480464 | CTD | |
| G | TP53 | tumor protein p53 |
|
multiple interactions | EXP | 17 | 7,571,720 | 7,590,868 | RGD:6480464 | CTD | |
| G | TP53 | tumor protein p53 |
|
multiple interactions | EXP | 17 | 7,571,720 | 7,590,868 | RGD:6480464 | CTD | |
| G | TP53 | tumor protein p53 |
|
multiple interactions | EXP | 17 | 7,571,720 | 7,590,868 | RGD:6480464 | CTD | |
| G | TP53 | tumor protein p53 |
|
increases activity | EXP | 17 | 7,571,720 | 7,590,868 | RGD:6480464 | CTD | |
| G | TP53 | tumor protein p53 |
|
increases expression | EXP | 17 | 7,571,720 | 7,590,868 | RGD:6480464 | CTD | |
| G | TP53 | tumor protein p53 |
|
increases expression | EXP | 17 | 7,571,720 | 7,590,868 | RGD:6480464 | CTD | |
| G | TP53 | tumor protein p53 |
|
multiple interactions | EXP | 17 | 7,571,720 | 7,590,868 | RGD:6480464 | CTD | |
| G | TP53 | tumor protein p53 |
|
increases activity | EXP | 17 | 7,571,720 | 7,590,868 | RGD:6480464 | CTD | |
| G | TP53I11 | tumor protein p53 inducible protein 11 |
|
multiple interactions | EXP | 11 | 44,953,899 | 44,972,857 | RGD:6480464 | CTD | |
| G | TP53I11 | tumor protein p53 inducible protein 11 |
|
decreases expression | EXP | 11 | 44,953,899 | 44,972,857 | RGD:6480464 | CTD | |
| G | TRPV6 | transient receptor potential cation channel, subfamily V, member 6 |
|
multiple interactions | EXP | 7 | 142,568,960 | 142,583,490 | RGD:6480464 | CTD | |
| G | TUBA4A | tubulin, alpha 4a |
|
increases expression | EXP | 2 | 220,115,001 | 220,118,638 | RGD:6480464 | CTD | |
| G | TXNRD1 | thioredoxin reductase 1 |
|
multiple interactions | EXP | 12 | 104,609,557 | 104,744,085 | RGD:6480464 | CTD | |
| G | TXNRD1 | thioredoxin reductase 1 |
|
multiple interactions | EXP | 12 | 104,609,557 | 104,744,085 | RGD:6480464 | CTD | |
| G | TYMP | thymidine phosphorylase |
|
multiple interactions | EXP | 22 | 50,964,181 | 50,968,514 | RGD:6480464 | CTD | |
| G | TYR | tyrosinase |
|
multiple interactions | EXP | 11 | 88,911,040 | 89,028,927 | RGD:6480464 | CTD | |
| G | TYR | tyrosinase |
|
multiple interactions | ISO | 11 | 88,911,040 | 89,028,927 | RGD:6480464 | CTD | |
| G | VCAM1 | vascular cell adhesion molecule 1 |
|
multiple interactions | ISO | 1 | 101,185,196 | 101,204,601 | RGD:6480464 | CTD | |
| G | VEGFA | vascular endothelial growth factor A |
|
multiple interactions | EXP | 6 | 43,737,946 | 43,754,224 | RGD:6480464 | CTD | |
| G | VEGFA | vascular endothelial growth factor A |
|
multiple interactions | EXP | 6 | 43,737,946 | 43,754,224 | RGD:6480464 | CTD | |
| G | VEGFA | vascular endothelial growth factor A |
|
multiple interactions | ISO | 6 | 43,737,946 | 43,754,224 | RGD:6480464 | CTD | |
| G | VEGFA | vascular endothelial growth factor A |
|
multiple interactions | ISO | 6 | 43,737,946 | 43,754,224 | RGD:6480464 | CTD | |
| G | VEGFA | vascular endothelial growth factor A |
|
multiple interactions | EXP | 6 | 43,737,946 | 43,754,224 | RGD:6480464 | CTD | |
| G | VMP1 | vacuole membrane protein 1 |
|
decreases expression | EXP | 17 | 57,784,863 | 57,917,954 | RGD:6480464 | CTD | |
| G | VMP1 | vacuole membrane protein 1 |
|
multiple interactions | EXP | 17 | 57,784,863 | 57,917,954 | RGD:6480464 | CTD | |
| G | XIAP | X-linked inhibitor of apoptosis |
|
decreases expression | EXP | X | 122,993,662 | 123,047,829 | RGD:6480464 | CTD | |
Term paths to the root
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




browse the term